Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Interest & Investment Income (2020 - 2025)

Historic Interest & Investment Income for Avidity Biosciences (RNA) over the last 6 years, with Q3 2025 value amounting to $14.7 million.

  • Avidity Biosciences' Interest & Investment Income fell 1794.3% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.9 million, marking a year-over-year increase of 4285.11%. This contributed to the annual value of $56.9 million for FY2024, which is 13728.52% up from last year.
  • Avidity Biosciences' Interest & Investment Income amounted to $14.7 million in Q3 2025, which was down 1794.3% from $14.5 million recorded in Q2 2025.
  • Avidity Biosciences' Interest & Investment Income's 5-year high stood at $18.5 million during Q4 2024, with a 5-year trough of $16000.0 in Q1 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $5.8 million (2023), whereas its average is $6.9 million.
  • Per our database at Business Quant, Avidity Biosciences' Interest & Investment Income plummeted by 8881.12% in 2021 and then surged by 779411.76% in 2022.
  • Over the past 5 years, Avidity Biosciences' Interest & Investment Income (Quarter) stood at $55000.0 in 2021, then soared by 4940.0% to $2.8 million in 2022, then skyrocketed by 131.06% to $6.4 million in 2023, then soared by 189.34% to $18.5 million in 2024, then dropped by 20.44% to $14.7 million in 2025.
  • Its Interest & Investment Income stands at $14.7 million for Q3 2025, versus $14.5 million for Q2 2025 and $16.2 million for Q1 2025.